Now PlayingEP. 1 Advancing IgA Nephropathy Care: Emerging Therapies, Unmet Needs, and Economic Considerations
EP. 3 Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines
Anti-Amyloid Therapy in Practice: Comparing Agents and Managing ARIA SafelyByKavita Nair, PhD,Joshua Oaks, MD,Scott Joy, MD, MBA, FACP,Jennifer Woodward, MD, MPH,Dylan Gallacher, PASeptember 14th 2026
Symptomatic Therapy Meets Disease Modification: Mapping the Alzheimer's Treatment ContinuumByKavita Nair, PhD,Joshua Oaks, MD,Scott Joy, MD, MBA, FACP,Jennifer Woodward, MD, MPH,Dylan Gallacher, PASeptember 14th 2026
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDDByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmDSeptember 11th 2026